Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of an Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma

NCT04644432 is registered in ClinicalTrials.gov with Herlev and Gentofte Hospital as lead sponsor.

NCT NCT04644432
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04644432 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of an Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma
Lead sponsor
Herlev and Gentofte Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
March 6, 2020
Completion date
September 6, 2022
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

kidney neoplasm, metastatic renal cell carcinoma, urogenital neoplasms, urologic neoplasms